Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PYGO2 is overexpressed in multiple myeloma patients with 1q21 amplification, driving plasma cell proliferation and cell cycle progression.

Cancer gene therapy·2026
Same author

Ligation-Driven Electrochemical Magneto-Genoassay Platform Based on PNA Probes for the Multiple Detection of Soy and Mustard DNA in Wheat Flour.

Biosensors·2026
Same author

Advancing CAR-NK cell therapy in solid tumors: Current landscape and future directions.

Cell reports. Medicine·2026
Same author

Inactivation of <i>Listeria innocua</i> and <i>Salmonella</i> spp. in traditional Italian <i>Spianata Piccante</i>: a comparative study of three formulations.

Italian journal of food safety·2026
Same author

Sheep erythrocyte potassium locus highlights MYADM family regulation of electroneutral potassium chloride cotransporters (KCC).

BMC genomics·2026
Same author

An engineered intradermal microneedle-array device enhances the cellular immune responses in a guinea pig model.

Frontiers in immunology·2026

Related Experiment Video

Updated: Mar 11, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.1K

BoHV-4-based vector delivering Ebola virus surface glycoprotein.

Alfonso Rosamilia1, Sarah Jacca1, Giulia Tebaldi1

  • 1Department of Medical-Veterinary Science, University of Parma, Via del Taglio 10, 43126, Parma, Italy.

Journal of Translational Medicine
|November 25, 2016
PubMed
Summary

A novel bovine herpesvirus 4 (BoHV-4) vector successfully delivered an Ebola virus glycoprotein (GP) gene. This approach generated a robust and long-lasting antibody response in goats, offering a promising platform for EBOV therapies.

Keywords:
Bovine herpesvirus 4Ebola virusRecombineeringVaccine platformViral vector

More Related Videos

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

7.4K
Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles
11:08

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

36.3K

Related Experiment Videos

Last Updated: Mar 11, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

37.1K
Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

7.4K
Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles
11:08

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

36.3K

Area of Science:

  • Virology
  • Immunology
  • Biotechnology

Background:

  • Ebola virus (EBOV) is a dangerous pathogen causing hemorrhagic fever, with limited treatment options.
  • Outbreaks are devastating, and high containment costs hinder EBOV research.
  • Innovative approaches are crucial for developing EBOV prophylactics and therapies.

Purpose of the Study:

  • To develop a novel antigen delivery platform for Ebola virus (EBOV) prophylactics.
  • To assess the potential of a recombinant bovine herpesvirus 4 (BoHV-4) vector for EBOV immunotherapy.

Main Methods:

  • A recombinant BoHV-4 vector (BoHV-4-syEBOVgD106ΔTK) was engineered to deliver a synthetic EBOV glycoprotein (GP) gene.
  • Goats were immunized with the BoHV-4-syEBOVgD106ΔTK vector.

Main Results:

  • The vector efficiently expressed EBOV GP in transduced cells without compromising viral replication.
  • Immunized goats developed high titers of anti-EBOV GP antibodies.
  • A long-lasting antibody response (up to 6 months) was observed, with no detectable viremia or secondary localization of the vector.

Conclusions:

  • The BoHV-4-based vector serves as an alternative antigen delivery system for vaccination.
  • This study demonstrates proof of principle for generating anti-EBOV antibodies in goats for potential immunotherapy.